Based in Inglewood, CA but having subsidiary operations in Tokyo, Japan, ImaginAb Inc is a bio-imaging company, structured around providing actionable insight into patient selection and treatment progress for cancer immunotherapy, enabling precision medicine. The company has developed a pipeline of imaging products that uses the specificity of monoclonal antibodies to create precise images of disease activity. Programs include a portfolio of precision imaging products, such as CD8 (IAB22M2C) and CD4 for immune-oncology; and PSMA PET (IAB2M) for prostate cancer. The effort is focused on re-engineering antibodies into smaller protein formats with kinetics optimized for diagnostic imaging. The firm is working on development of a pipeline of targeted molecular imaging agents for unmet clinical needs in oncology and immunology to include products for prostate and pancreatic cancers and is also developing companion imaging agents based on therapeutic antibody pipelines. Its technology enables a therapeutic mAb or ADC to be re-engineered into an imaging agent that has biospecificity of the âparentâ product with kinetics for clinical imagin
